

Plasma nitric oxide metabolite levels increase during successive exercise stress testing – A link to delayed ischemic preconditioning?

Dumitru Zdrengea MD PhD¹, György Bódizs MD PhD², Mihai Claudiu Ober MD³, Maria Ilea MD⁴

D Zdrengea, G Bódizs, MC Ober, M Ilea. Plasma nitric oxide metabolite levels increase during successive exercise stress testing – A link to delayed ischemic preconditioning? *Exp Clin Cardiol* 2003;8(1):26-28.

BACKGROUND: Animal studies have shown that nitric oxide is involved in delayed ischemic preconditioning.

OBJECTIVES: To determine whether plasma nitrates and nitrites (NO_x^- , as measure of nitric oxide) are modified by two consecutive effort tests and whether these changes translate into clinical improvement

METHODS: Twenty-two patients with ischemic heart disease each performed two effort tests at 24-h intervals. Plasma NO_x^- level was determined and compared before and after both stress tests. Peak effort, double product at peak effort and maximal ST segment depression were considered clinical endpoints and were compared between the two tests.

RESULTS: Plasma NO_x^- increased slightly after the first exercise test compared with pretest value ($17.05 \pm 1.6 \mu\text{mol/mL}$ versus $15.38 \pm 1.4 \mu\text{mol/mL}$). In turn, after the second test there was a significant rise in NO_x^- level ($23.65 \pm 2.2 \mu\text{mol/mL}$ versus $15.10 \pm 1.3 \mu\text{mol/mL}$, $P < 0.03$). The pretest values were almost identical between the two tests. Peak effort and double product at peak effort remained unchanged between the two tests. Although ischemic stress was the same, ST depression was significantly lower ($P < 0.01$) for the second test ($0.85 \pm 0.06 \text{ mm}$ versus $1.73 \pm 0.16 \text{ mm}$).

CONCLUSION: Our study shows an increased plasma NO_x^- level after the second of two consecutive exercise stress tests at 24-h intervals, along with a decrease of electrocardiographic consequences of approximately the same ischemic stress. These findings are consistent with experimental data in animals, which point to nitric oxide as a trigger and effector of ischemic preconditioning.

Key Words: Delayed preconditioning; Exercise; Nitrate; Nitric oxide; Nitrite

Delayed ischemic preconditioning is generally considered the mechanism of the favourable effect of a previous angina on outcome in acute myocardial infarction patients (1-3). It could also be the cause of decreased maximal ST depression under a similar ischemic stress during successive exercise stress testing (4,5) or of the increase in myocardial workload at which similar effects (eg, the same ST depression or angina) occur.

The mechanism of delayed preconditioning seems to involve nitric oxide (NO) as both a trigger and a mediator of the phenomenon (6-8). It was shown that a first ischemic episode increases NO production via constitutive endothelial nitric oxide synthase (eNOS). NO is one of the triggers for transcription of inducible nitric oxide synthase (iNOS) resulting in greater NO production during a second ischemic episode (24 h later), which mediates the protective effect.

Such an increase in NO production during the second ischemic episode was not shown in humans until now.

The purpose of our study was to investigate NO production before and after two consecutive exercise stress tests at 24-h intervals.

METHODS

The study involved 22 patients with ischemic heart disease, which was confirmed by coronary angiography. Thirteen patients presented with stable effort angina and nine patients with old myocardial infarction. Of these, 18 patients were males and four

were females, aged 41 to 74 years (mean 56.2 ± 1.6 years). Patients with resting electrocardiogram (ECG) changes that would make exercise ECG difficult to interpret (ie, conduction disturbances, hypertrophy), were excluded.

For all patients, current medications including anti-ischemic drugs were maintained unchanged during the study, but nitrates were excluded a week before.

Exercise protocol: All patients performed two maximal, symptom-limited exercise tests (ETs) on the cycloergometer at 24-h intervals (ET_1 and ET_2), under supervision of the same experienced physician. Both ET_1 and ET_2 were performed in the morning, according to classical protocols (9,10), in increments of 25 W and 2.5 min duration. One bipolar lead ($\text{V}_5\text{-V}_5\text{R}$) was continuously monitored during the tests and was recorded during the last minute of every step and at peak exercise. During the recovery phase, a 12-lead ECG was recorded at 1 min, and every 2 min after, until 9 min or until angina and ECG changes disappeared. ECG was automatically analyzed for ST changes at 0.06 s from the J point. Maximal ST depression was considered in lead $\text{V}_5\text{-V}_5\text{R}$ during exercise or in the lead with maximum ST depression if that appeared only in the recovery phase. Blood pressure was manually measured by the same pattern as the ECG recording. A test was considered positive if a maximum ST depression of at least 0.1 mV occurred.

The positivity of ET_1 represented the including criterion. ET_2 was performed after 24 h in similar conditions.

¹Chief of Cardiology Department, Rehabilitation Clinical Hospital, Professor of Cardiology, University of Medicine and Pharmacy, Cluj-Napoca;

²Clinical Laboratory, Rehabilitation Clinical Hospital, Cluj-Napoca; ³Cardiology Department, County Clinical Hospital, PhD candidate,

University of Medicine and Pharmacy, Cluj-Napoca; and ⁴Cardiology Department, Rehabilitation Clinical Hospital, PhD candidate, University of Medicine and Pharmacy, Rehabilitation Clinical Hospital, Cluj-Napoca, Romania

Correspondence: Dr Dumitru Zdrengea, Spitalul Clinic de Recuperare, 3400, Cluj-Napoca, Cluj, Str. Viilor, 46-50, Romania. Telephone 40-264-438940, fax 40-264-453131, e-mail mober@pcnet.ro

TABLE 1
Hemodynamic, workload and medication data

	Pre-ET ₁	Pre-ET ₂	P*	Peak ET ₁	Peak ET ₂	P**
sBP (mmHg)	131±3.5	136±3.7	NS	170±6.1	173±5.7	NS
dBP (mmHg)	84±1.9	87±1.8	NS	96±2.7	101±2.4	NS
mBP (mmHg)	100±2.3	104±2.1	NS	125±3.4	127±2.8	NS
HR (min ⁻¹)	72±3.2	67±2.5	0.01	109±6.0	103±5.2	NS
DP (mmHg/min)	9474±503	9184±498	NS	21224±2344	22300±2400	NS
Workload (W)	–	–	–	79.3±7.1	80.3±7.4	NS

Medications expressed as number of patients (percentage): acetylsalicylic acid 22 (100%), beta-blocker 22 (100%), angiotensin-converting enzyme inhibitor 20 (91%), calcium blocker 3 (14%), nitrate 0 (0%). *Comparing pre-ET₁ and pre-ET₂ values. ** Comparing peak ET₁ and peak ET₂ values. dBP Diastolic blood pressure; DP Double product; ET₁ First exercise test; ET₂ Second exercise test; HR Heart rate; mBP Mean blood pressure; sBP Systolic blood pressure

For both ET₁ and ET₂, the following parameters were analyzed: peak effort (as a measure of maximum systemic oxygen uptake [VO_{2max}]), heart rate, blood pressure and double product (DP) at peak effort (as a measure of maximum myocardial oxygen demand [peak MVO₂]) and maximal ST depression.

Nitrates/nitrites determination: It has been shown that plasma nitrates or sum of nitrates/nitrites are measures of endogenous NO production (11). Blood samples were obtained for quantitation of nitrates/nitrites before and after each exercise stress test. Post-test samples were obtained during the recovery phase. In order to determine the level of nitrate/nitrite (NO_x⁻), plasma was incubated with reduced nicotinamide adenine dinucleotide phosphate (NADPH) and NADPH-dependent nitrate reductase to convert nitrates to nitrites. Afterwards, the nitrites level was determined by the Griess method (11), using a commercially available analysis kit (Griess Reagent System, Promega Corp, USA) and expressed as μmol/mL. The investigators who performed ETs and NO_x⁻ determinations were blinded to the other investigators' results.

Statistical analysis: Data were compared before and after every ET or between the two ETs (as necessary) using Student's paired *t* test. Data are expressed as mean ± SE. P<0.05 was considered statistically significant.

RESULTS

The hemodynamic, workload and medication data on the two tests are presented in Table 1. The analysis of the peak effort as a measure of VO_{2max} revealed no significant difference between ET₁ and ET₂. The mean values of the DP at peak effort, as a measure of peak MVO₂, were also very close during ET₁ and ET₂. Blood pressure and heart rate at peak exercise were identical for both tests (Table 1).

In turn, maximal ST depression (Table 2) during ET₂ was significantly less than maximal ST depression during ET₁, P<0.01. In five patients (22.7%), the ET₂ became negative (ST depression less than 1 mm).

The plasma NO_x⁻ level immediately after ET₁ was only slightly higher than rest value before ET₁. After 24 h, before ET₂, the resting NO_x⁻ level was about the same as before ET₁. In turn, after ET₂, the plasma NO_x⁻ level was significantly (P<0.03) higher than both values before ET₁ and ET₂ (Table 2).

DISCUSSION

Our study shows that the plasma NO_x⁻ level increases slightly during ET₁ and significantly during ET₂, and there is a significant decrease of ST depression during ET₂, with peak MVO₂

TABLE 2
Plasma nitrate/nitrite (NO_x⁻) and ST depression results

	ET ₁		ET ₂		P*
	Pre-ET	Post-ET	Pre-ET	Post-ET	
NO _x ⁻ level (μmol/mL)	15.38±1.4	17.05±1.6	15.10±1.3	23.65±2.2**	NS
ST depression (mm)	1.73±0.16		0.85±0.06		<0.01

*Comparing pre-test NO_x⁻ level and maximal ST depression at ET₁ and ET₂. **Significantly higher (P<0.03) versus pre-ET₂ value. ET Exercise test; ET₁ and ET₂ First and second exercise tests, respectively

remaining unchanged between the two tests. The attenuation of ECG ischemia during a similar ischemic stress is probably an expression of ischemic preconditioning. Because the protection was observed 24 h after the preconditioning episode, it was attributed to delayed ischemic preconditioning, considering that early preconditioning operates only in the first 2 h after the preconditioning episode (12,13). The observed pattern of evolution of plasma NO_x⁻ level is compatible with the theory that NO is a mediator of delayed ischemic preconditioning, alone or together with other mechanisms.

The maximal workload and peak DP during the two consecutive ETs at 24 h were very close. This suggests that training effect or changes of collateral circulation do not influence the parameters reached during ET₂ (14).

The contribution of early preconditioning to decreasing maximal ST depression during consecutive exercise testing at 30-min intervals was proved by Tomai et al (15,16) and confirmed by Zdrenghea et al (17). However, studies of delayed preconditioning during consecutive exercise stress testing yielded conflicting results. Two previous studies (4,18) revealed less ST depression during a second ET at 24-h intervals, as in the present study. However, Tomai et al (16) found no delayed protective effect of exercise-induced ischemia.

It was demonstrated experimentally in animals that the preconditioning ischemic episode increases NO production (by eNOS) and other mediators (adenosine, reactive oxygen species) which act synergistically as triggers for the iNOS transcription; the level of the enzyme increases after 24 h and lasts for 72 h (7,8). During this interval of time, a new ischemic episode will result in increased NO production with a decrease of the consequences of myocardial ischemia, the mechanisms of which are only partially known (19,20). However, delayed ischemic preconditioning appears to be a heterogeneous phenomenon, involving multiple inter-related effectors, both NO-dependent and NO-independent (20).

In a recent study (21), nitroglycerin (a NO donor) protected myocardium against PTCA-induced ischemia between 24 h to 72 h after its discontinuation. This supports the hypothesis that NO is not only an effector (as in our study) but also a trigger of delayed ischemic preconditioning.

All clinical studies on preconditioning, including ours, have some inherent limitations because of ethical reasons. Consequently, data are indirect and do not reveal the intimate mechanisms of changes observed.

Given these limitations, we cannot exclude subtle changes of myocardial perfusion from one ET to another, although maximum MVO_2 remained relatively unchanged.

In addition, we cannot identify the source of NO by systemic plasma NO_x^- quantitation. There is evidence that NO can be increased by shear stress, through constitutive NO synthases (22,23), in different cells. These sources of NO could be stimulated by increased perfusion on exercise.

REFERENCES

1. Abete P, Ferrara N, Cacciatore F, et al. High level of physical activity preserves the cardioprotective effect of preinfarction angina in elderly patients. *J Am Coll Cardiol* 2001;38:1357-65.
2. Kloner RA, Shook T, Przyklenk K, et al, for the TIMI 4 investigators. Previous angina alters hospital outcome in TIMI 4. A clinical correlate to preconditioning? *Circulation* 1995;91:37-47.
3. Noda T, Minatoguchi S, Fujii K, et al. Evidence for the delayed effect in human ischemic preconditioning. Prospective multicenter study for preconditioning in acute myocardial infarction. *J Am Coll Cardiol* 1999;34:1966-74.
4. Zdrenghea D, Giurgea N, Ilea M, Potâng E. Preconditionarea ischemica tardiva evidentiata prin teste de efort succesive. *Revista Româna de Cardiologie* 2000;10:57-60.
5. Zdrenghea D, Potâng E, Timis D, Bogdan E. Does ischemic preconditioning occur during rehabilitation of ischemic patients? *Rom J Intern Med* 1999;37:201-6.
6. Bolli R, Bhatti ZA, Tang XL, et al. Evidence that late preconditioning against myocardial stunning in conscious rabbits is triggered by the generation of nitric oxide. *Circ Res* 1997;81:42-52.
7. Bolli R, Manchikalapudi S, Tang XL, et al. The protective effect of late preconditioning against myocardial stunning in conscious rabbits is mediated by nitric oxide synthase. Evidence that nitric oxide acts both as a trigger and as a mediator of the late phase of ischemic preconditioning. *Circ Res* 1997;81:1094-107.
8. Guo Y, Jones WK, Xuan Y-T, et al. The late phase of ischemic preconditioning is abrogated by targeted disruption of the iNOS gene. *Proc Natl Acad Sci USA* 1999;96:11507-12.
9. Zdrenghea D. Testarea de stress in cardiopatia ischemica. Cluj-Napoca RO, ed. Cluj-Napoca: Sincron, 1993.
10. Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 guideline update for exercise testing: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing). *Circulation* 2002;106:1883-92.
11. Zeballos GA, Bernstein RD, Thompson CI. Pharmacodynamics of plasma nitrate/nitrite as an indication of nitric oxide formation in conscious dogs. *Circulation* 1995;91:2982-8.
12. Yellon DM, Baxter GF. A "second window of protection" or delayed preconditioning phenomenon: future horizons for myocardial protection? *J Mol Cell Cardiol* 1995;27:1023-34.
13. Murry CE, Richard VJ, Reimer KA, Jennings RB. Ischemic preconditioning slows energy metabolism and delays ultrastructural damage during a sustained ischemic episode. *Circ Res* 1990;66:913-31.
14. Zdrenghea D. *Recuperarea bolnavilor cardiovasculari*. Cluj-Napoca RO, Ed. Cluj-Napoca: Clusium, 1995.
15. Tomai F, Crea F, Danesi A, et al. Mechanisms of the warm-up phenomenon. *Eur Heart J* 1996;17:1022-7.
16. Tomai F, Perino M, Ghini AS, et al. Exercise-induced myocardial ischemia triggers the early phase of preconditioning but not the late phase. *Am J Cardiol* 1999;83:586-8.
17. Zdrenghea D, Ilea M, Predescu D, Potâng E. Ischemic preconditioning during successive exercise testing. *Rom J Intern Med* 1998;36:161-5.
18. Bilinska M, Rudnicki S, Beresewicz A. Delayed attenuation of myocardial ischemia with repeated exercise in subjects with stable angina: a possible model for the second window of protection? *Basic Res Cardiol* 2000;95:418-23.
19. Rakhit RD, Marber MS. Nitric oxide: an emerging role in cardioprotection? *Heart* 2001;86:368-72.
20. Bolli R. The late phase of preconditioning. *Circ Res* 2000;87:972-83.
21. Leesar MA, Stoddard MF, Dawn B, et al. Delayed preconditioning-mimetic action of nitroglycerin in patients undergoing coronary angioplasty. *Circulation* 2001;103:2935-41.
22. Hori N, Wiest R, Groszmann RJ. Enhanced release of nitric oxide in response to changes in flow and shear stress in the superior mesenteric arteries of portal hypertensive rats. *Hepatology* 1998;28:1467-73.
23. Papadaki M, Tilton RG, Eskin SG, McIntire LV. Nitric oxide production by cultured human aortic smooth muscle cells: Stimulation by fluid flow. *Am J Physiol* 1998;274:H616-26.
24. Sarkar D, Vallance P, Harding SE. Nitric oxide: Not just a negative inotrope. *Eur J Heart Fail* 2001;3:527-34.
25. Costa F, Christensen NJ, Farley G, Biaggioni I. NO modulates norepinephrine release in human skeletal muscle: Implications for neural preconditioning. *Am J Physiol Regul Integr Comp Physiol* 2001;280:R1494-8.